Cytomos
Edinburgh
About Cytomos
Cytomos® develops and provides integrated, predictive analytics systems for intelligent bioprocessing in biopharma and cell therapy domains. Built upon our patented Cytomos® Dielectric Spectroscopy (CDS™) technology, our systems are unbiased, have single-cell resolution and are scalable across all upstream production stages. Leveraging the unmatched data depth per cell provided by CDS™, our proprietary machine learning (ML) algorithms provide insights into your bioprocesses like never before.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $13.6M
- Last round: Series Unknown (Nov 2024)
- Website: cytomos.com
- Phone: +44 131 272 2770
Industries & Categories
Biopharma, Biotechnology, Machine Learning, Medical
Social Profiles
Canonical: https://fsome.com/organization/cytomos-70298 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.